Grifols, S.A. (GRFS)

USD 7.0

(0.65%)

EBITDA Summary of Grifols, S.A.

  • Grifols, S.A.'s latest annual EBITDA in 2023 was 1.18 Billion EUR , up 6.1% from previous year.
  • Grifols, S.A.'s latest quarterly EBITDA in 2024 Q2 was 364.51 Million EUR , down 0.0% from previous quarter.
  • Grifols, S.A. reported an annual EBITDA of 1.21 Billion EUR in 2022, up 16.4% from previous year.
  • Grifols, S.A. reported an annual EBITDA of 922.27 Million EUR in 2021, down -29.71% from previous year.
  • Grifols, S.A. reported a quarterly EBITDA of 347.53 Million EUR for 2024 Q1, up 4.81% from previous quarter.
  • Grifols, S.A. reported a quarterly EBITDA of 331.57 Million EUR for 2023 Q4, up 32.35% from previous quarter.

Annual EBITDA Chart of Grifols, S.A. (2023 - 2005)

Created with Highcharts 11.1.0YearsEBITDA2006200820102012201420162018202020220 USD500000000 USD1000000000 USD1500000000 USD

Historical Annual EBITDA of Grifols, S.A. (2023 - 2005)

Year EBITDA EBITDA Growth
2023 1.18 Billion EUR 6.1%
2022 1.21 Billion EUR 16.4%
2021 922.27 Million EUR -29.71%
2020 1.29 Billion EUR -8.78%
2019 1.42 Billion EUR 23.48%
2018 1.22 Billion EUR 0.98%
2017 1.28 Billion EUR 4.61%
2016 1.14 Billion EUR 0.01%
2015 1.16 Billion EUR 11.07%
2014 1.04 Billion EUR 21.86%
2013 864.58 Million EUR 6.86%
2012 776.26 Million EUR 111.56%
2011 341.42 Million EUR 54.66%
2010 233.65 Million EUR -6.12%
2009 255.94 Million EUR 5.48%
2008 243.67 Million EUR 27.77%
2007 190.71 Million EUR 117.48%
2006 100.94 Million EUR 35.77%
2005 75.99 Million EUR 0.0%

Peer EBITDA Comparison of Grifols, S.A.

Name EBITDA EBITDA Difference
Amgen Inc. 12.23 Billion USD 90.339%
AstraZeneca PLC 12.97 Billion USD 90.892%
Biogen Inc. 2.37 Billion USD 50.274%
Gilead Sciences, Inc. 10.49 Billion USD 88.739%
MIRA Pharmaceuticals, Inc. - USD -Infinity%
Scilex Holding Company -109.1 Million USD 1183.366%
Scilex Holding Company -109.1 Million USD 1183.366%